Two AstraZeneca therapies accepted in Scotland
Tezspire is a drug for severe asthma and Forxiga is used to treat chronic heart failure
Read More
Tag: heart
EU approves AstraZeneca Forxiga for use across the EU
Milestone therapy concerns the treatment of patients with symptomatic chronic heart failure
Read More
Diabetes patients to benefit from £10m heart disease data investment
The British Heart Foundation’s project will accelerate the search for better prevention and treatment of diabetes
Read More
First treatment for ‘broken heart syndrome’ trialled
Scientists will trial a programme of exercise conditioning and psychological therapy for people diagnosed with the condition
Read More
First treatment for adults across full spectrum of chronic heart failure
Largest unmet need in cardiovascular medicine finally receives approved therapy
Read More
CV patients finding it harder to get treatment during pandemic
The BHF is calling on the government to address the issue or the backlog will continue to grow putting patients at risk of getting sicker
Read More
US OK’s AZ’ Farxiga for heart failure with reduced ejection fraction
Farxiga is the first sodium glucose co-transporter 2 inhibitor cleared by the FDA to treat heart failure with reduced ejection fraction
Read More
Rise in heart and circulatory disease deaths
The worrying rise bucks decades of progress that has seen annual deaths from heart and circulatory disease half since the 1960s.
Read More
NHS to offer new non-invasive procedure for patients with faulty heart valve
An innovative, non-invasive procedure to repair faulty valves in the heart has been approved by the National Institute for Health and Care Excellence for use on the NHS.
Read More
80% at risk of early death because of an aged heart, warns PHE
Four in five people have a heart age older than their real age, leaving them at risk of early death from cardiovascular disease, Public Health England data show.
Read More
FDA approves heart protection label change for Repatha
US regulators have approved Amgen’s Repatha as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularisations in adults with cardiovascular disease.
Read More
Hundreds of thousands in the UK unaware of sudden death risk
The British Heart Foundation has estimated that 620,000 people in the UK are carrying a carrying a faulty gene that puts them at high risk sudden death, but warns that the majority are unaware of this.
Read More
